Abbvie Inc. | Date: 2016-06-30
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Abbvie Inc. | Date: 2016-09-15
Engineered multispecific binding proteins that bind at least one ligand for a receptor are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.
Abbvie Inc. | Date: 2016-11-16
The instant invention relates to modulated lysine variant species compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such modulated lysine variant species compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF is detrimental, are also provided.
Abbvie Inc. | Date: 2017-01-27
The instant invention relates to the field of protein production, and in particular to compositions and processes for controlling and limiting the heterogeneity of proteins expressed in host cells.
Abbvie Inc. | Date: 2016-11-04
The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells.
Abbvie Inc. | Date: 2017-05-17
Adapters for a connector assembly for percutaneous tubing are provided. A male adapter (fig. 22a, 1000) includes a connector fitting (1002) proximate a first end, the connector fitting configured to join to a connector for a tubing system or device, and a male connector (656) proximate a second end. The male connector includes a plug end with a fluid lumen defined therethrough, the plug end having a circumferential groove defined therein to receive a locking extension of a female connector sized to be received within the circumferential groove of the plug end to allow the female connector to rotate relative to and maintain axial engagement with the male connector when the locking extension is received within the groove. An adapter having a female connector (fig. 24, 1300) is also provided.
Abbvie Inc. | Date: 2017-02-06
Protein glycosylation greatly influences the structure, function, and pharmacokinetics of recombinant proteins. Here, growth media supplemented with metal ions is shown to modulate the protein glycosylation profile of recombinant proteins expressed in a variety of eukaryotic cell lines. In particular, millimolar amounts of ferric salts (e.g. ferric nitrate, ferric citrate, etc.) significantly increased the percentage of galactosylated N-glycan species. The effect on protein glycosylation was concentration-dependent manner up to 1.0 mM across multiple cell lines without adverse effects on cell viability. The use of iron supplements in cell culture media provides an efficient and effective approach towards the specific re-targeting of N-glycan glycoform profiles of recombinantly expressed proteins.
Abbvie Inc. | Date: 2017-02-08
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
Abbvie Inc. and Apogenix | Date: 2017-03-01
Provided herein are specific TRAIL receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TRAIL-associated disease or disorder. The TRAIL receptor agonist proteins provided herein comprise three soluble TRAIL domains and an Fc fragment. The TRAIL receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
Abbvie Inc. | Date: 2017-01-18
The present invention pertains to derivatives of tylosin A. In particular, the present invention pertains to compounds having a structure of Formula (I). The present invention also pertains to compositions comprising derivatives of tylosin A and methods of treating or preventing conditions or disorders using such compounds and compositions.